SEARCH

SEARCH BY CITATION

References

  • Ai T, Bompadre SG, Wang X, Hu S, Li M, Hwang T-C (2004). Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 65: 14151426.
  • Akiyama T, Ogawara H (1991). Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol 201: 362370.
  • Amaral MD (2005). Processing of CFTR: traversing the cellular maze––how much CFTR needs to go through to avoid cystic fibrosis Pediatr Pulmonol 39: 479491.
  • Amaral MD, Kunzelmann K (2007). Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 28: 334341.
  • Bebök Z, Venglarik CJ, Pánczél Z, Jilling T, Kirk KL, Sorscher EJ (1998). Activation of ΔF508 CFTR in an epithelial monolayer. Am J Physiol 275: C599C607.
  • Bernier V, Lagace M, Bichet DG, Bouvier M (2004). Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 15: 222228.
  • Bulteau-Pignoux L, Dérand R, Métayé T, Joffre M, Becq F (2002). Genistein modifies the activation kinetics and magnitude of phosphorylated wild-type and G551D-CFTR chloride currents. J Membr Biol 188: 175182.
  • Cai Z, Chen J-H, Hughes LK, Li H, Sheppard DN (2007). The physiology and pharmacology of the CFTR Cl channel. In: Pusch M (ed). Chloride Movements across Cellular Membranes. Elsevier Limited: San Diego. pp 109143.
  • Cai Z, Taddei A, Sheppard DN (2006). Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl channel. J Biol Chem 281: 19701977.
  • Carson MR, Travis SM, Welsh MJ (1995). The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. J Biol Chem 270: 17111717.
  • Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA et al. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63: 827834.
  • Cui L, Aleksandrov L, Chang X-B, Hou Y-X, He L, Hegedus T et al. (2007). Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol 365: 981994.
  • Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D et al. (1991). Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation. Nature 354: 526528.
  • Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ (1992). Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761764.
  • Farinha CM, Nogueira P, Mendes F, Penque D, Amaral MD (2002). The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 366: 797806.
  • Fischer H, Machen TE (1994). CFTR displays voltage dependence and two gating modes during stimulation. J Gen Physiol 104: 541566.
  • Gadsby DC, Vergani P, Csanády L (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 440: 477483.
  • Hille B (2001). Ionic Channels of Excitable Membranes 3rd edn. Sinauer Associates Inc.: Sunderland, MA.
  • Hwang T-C, Koeppe II RE, Andersen OS (2003). Genistein can modulate channel function by a phosphorylation-independent mechanism: importance of hydrophobic mismatch and bilayer mechanics. Biochemistry 42: 1364613658.
  • Hwang T-C, Sheppard DN (1999). Molecular pharmacology of the CFTR Cl channel. Trends Pharmacol Sci 20: 448453.
  • Hwang T-C, Wang F, Yang ICH, Reenstra WW (1997). Genistein potentiates wild-type and ΔF508-CFTR channel activity. Am J Physiol 273: C988C998.
  • Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83: 129135.
  • Lansdell KA, Cai Z, Kidd JF, Sheppard DN (2000). Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl channels expressed in murine cell line. J Physiol 524: 317330.
  • Lansdell KA, Kidd JF, Delaney SJ, Wainwright BJ, Sheppard DN (1998). Regulation of murine cystic fibrosis transmembrane conductance regulator Cl channels expressed in Chinese hamster ovary cells. J Physiol 512: 751764.
  • Lehrich RW, Aller SG, Webster P, Marino CR, Forrest Jr JN (1998). Vasoactive intestinal peptide, forskolin, and genistein increase apical CFTR trafficking in the rectal gland of the spiny dogfish, Squalus acanthias: acute regulation of CFTR trafficking in an intact epithelium. J Clin Invest 101: 737745.
  • Li H, Findlay IA, Sheppard DN (2004). The relationship between cell proliferation, Cl secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int 66: 19261938.
  • Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL (2004). Modulation of ΔF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 31: 351357.
  • Lindemann B, Van Driessche W (1977). Sodium-specific membrane channels of frog skin are pores: current fluctuations reveal high turnover. Science 195: 292294.
  • Mendes F, Wakefield J, Bachhuber T, Barroso M, Bebok Z, Penque D et al. (2005). Establishment and characterization of a novel polarized MDCK epithelial cellular model for CFTR studies. Cell Physiol Biochem 16: 281290.
  • Moran O, Galietta LJV, Zegarra-Moran O (2005). Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 62: 446460.
  • Randak C, Auerswald EA, Assfalg-Machleidt I, Reenstra WW, Machleidt W (1999). Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide binding fold of cystic fibrosis transmembrane conductance regulator by genistein. Biochem J 340: 227235.
  • Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 10661073.
  • Rowe SM, Miller S, Sorscher EJ (2005). Cystic fibrosis. N Engl J Med 352: 19922001.
  • Scott-Ward TS, Li H, Schmidt A, Cai Z, Sheppard DN (2004). Direct block of the cystic fibrosis transmembrane conductance regulator Cl channel by niflumic acid. Mol Membr Biol 21: 2738.
  • Sears CL, Firoozmand F, Mellander A, Chambers FG, Eromar IG, Bot AGM et al. (1995). Genistein and tyrphostin 47 stimulate CFTR-mediated Cl secretion in T84 cell monolayers. Am J Physiol 269: G874G882.
  • Sheppard DN, Robinson KA (1997). Mechanism of glibenclamide inhibition of cystic fibrosis transmembrane conductance regulator Cl channels expressed in a murine cell line. J Physiol 503: 333346.
  • Sheppard DN, Welsh MJ (1999). Structure and function of the cystic fibrosis transmembrane conductance regulator chloride channel. Physiol Rev 79: S23S45.
  • Van Goor F, Straley KS, Cao D, González J, Hadida S, Hazlewood A et al. (2006). Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol 290: L1117L1130.
  • Venglarik CJ, Schultz BD, DeRoos ADG, Singh AK, Bridges RJ (1996). Tolbutamide causes open channel blockade of cystic fibrosis transmembrane conductance regulator Cl channels. Biophys J 70: 26962703.
  • Venglarik CJ, Schultz BD, Frizzell RA, Bridges RJ (1994). ATP alters current fluctuations of cystic fibrosis transmembrane conductance regulator: evidence for a three-state activation mechanism. J Gen Physiol 104: 123146.
  • Vergani P, Nairn AC, Gadsby DC (2003). On the mechanism of MgATP-dependent gating of CFTR Cl channels. J Gen Physiol 120: 1736.
  • Wang F, Zeltwanger S, Yang ICH, Nairn AC, Hwang T-C (1998). Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating: evidence for two binding sites with opposite effects. J Gen Physiol 111: 477490.
  • Wang Y, Bartlett MC, Loo TW, Clarke DM (2006). Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70: 297302.
  • Welsh MJ, Ramsey BW, Accurso F, Cutting GR (2001). Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill Inc.: New York. pp 51215188.